EyeCool Therapeutics adds ophthalmology veteran Richard Lindstrom to board

EyeCool Therapeutics appointed ophthalmologist Richard L. Lindstrom, MD, to its Board of Directors on Oct. 1, 2026, as the company prepares to start its U.S. clinical program for ETX-4143. The move adds deep clinical and commercialization experience to the clinical-stage device maker focused on chronic ocular surface pain.

Why it matters: - EyeCool Therapeutics is trying to establish precision ocular cooling as a new treatment category for chronic ocular surface pain. - Adding Richard L. Lindstrom to the board gives the company a high-profile ophthalmology leader with experience in clinical development, evaluation and adoption of eye technologies. - The appointment comes as EyeCool prepares to begin its U.S. clinical program for ETX-4143, its investigational in-office cooling device.

What happened: - EyeCool Therapeutics announced Oct. 1, 2026, that it appointed Richard L. Lindstrom, MD, to its Board of Directors. - Lindstrom is an internationally recognized ophthalmologist, surgeon, researcher, educator and innovator. - EyeCool said the appointment was effective immediately.

The details: - Lindstrom’s career has focused on corneal, cataract, refractive and anterior-segment ophthalmology. - He is the founder and attending surgeon emeritus of Minnesota Eye Consultants. - He is adjunct professor emeritus in the Department of Ophthalmology at the University of Minnesota. - Lindstrom has held leadership, advisory and board roles across ophthalmology. - EyeCool said his appointment adds clinical, scientific and commercialization expertise as the company advances ETX-4143. - ETX-4143 is designed to provide fast, lasting relief for patients suffering from chronic ocular surface pain. - Clinical work completed in Australia to date supports the scientific rationale for precision ocular cooling in this condition. - EyeCool is preparing to initiate its U.S. clinical program. - The company warned that ETX-4143 has not been approved or cleared for marketing by the U.S. Food and Drug Administration and remains an investigational device. - EyeCool describes itself as a clinical-stage medical device company focused on precision ocular cooling. - More information is available on EyeCool Therapeutics' website.

Between the lines: - Lindstrom’s board appointment signals that EyeCool wants greater credibility with clinicians and investors as it moves from early clinical evidence toward U.S. studies. - His public remarks suggest the Australian program is an important proof point for the company’s broader strategy. - The FDA disclosure underscores that the technology is still in the development stage, even as EyeCool highlights therapeutic potential.

What's next: - EyeCool plans to move into its U.S. clinical program for ETX-4143. - The company will likely use that next stage to build additional evidence on safety, performance and patient benefit. - Lindstrom is expected to support the team as it advances U.S. clinical development.